ResApp announces collaboration

Company News

ResApp Health Limited (ASX:RAP) has partnered up with a humanitarian organisation and UniQuest to field test ResApp’s smartphone-based pneumonia diagnostic tool.
Under the memorandum of understanding, the three organisations will work together to secure one or more field sites in the developing world.
Subject to approval by local human research ethics committees, field sites are expected to be up-and-running in mid 2016.
CEO and Managing Director, Dr Tony Keating said the collaboration provided exposure to the difficult environments in which personnel operate, providing opportunity to refine the company’s diagnostic tool to suit.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.